Medical network - March 27 foreign drug firms usher in the spring breeze waves. Recently, the CFDA formally approved the Pfizer citrate oral JAK inhibitor for the occasional method cloth (also known as folic acid for the occasional method) applications, this is the fourth imports this year thanks to priority review. On November 6, 2012, the product on the market in the United States for the first time, according to data from 2016, this product has been in the global sales of over $927 million, at present there are 28 companies won the domestic clinical approval of tablet or API. 

 

2017 is expected to break through the $1 billion mark 

 

Citrate for the occasional method was approved for curative effect of methotrexate or inadequate for its tolerance of the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients, but with methotrexate anti-rheumatism medicine or other non-biological improve disease (DMARD) used in combination. 

 

Data show that folic acid for the occasional method of Pfizer has now been more than 50 countries around the world approved to use, the drug was also the European Union for resistance rheumatism (EULAR), the American rheumatism association (ACR), asia-pacific rheumatology association federation (APLAR), and other international organizations, the recommended treatment guidelines. 

 

, according to data in recent five years, citrate for the occasional method of Pfizer's global sales climbed, more than $2016 in 927 million, the growth rate of 77.25%. 2017 will be the key to the product through the billion a year, once upon a time a few years of rising trend, expected can easily pass, Pfizer's global blockbuster products will add a valiant soldier. 

 

There are 28 domestic enterprises has been approved for clinical 

 

 

 

, according to the current citrate method for his image (citrate method for cloth) in domestic has 23 QiHuo group of clinical, starting from the review to the approval of state, is the earliest approved zhengda pharmaceutical group co., LTD., the weather is fine. 

 

Can be obtained from table 2, a total of 24 medicine QiHuo batch of citrate for the occasional method, (citrate method for cloth) clinical application of active pharmaceutical ingredients. Table 1 mentioned 23 drug firms, there are 19 also approved the clinical application of active pharmaceutical ingredients. Among them, the API is the earliest approved clinical orsay kang pharmaceutical co., LTD., jiangsu province. The statistics, a total of 28 drug firms approved by the drug tablet or apis in clinical. 

 

Domestic rheumatoid arthritis drug market size exceeds 11.5 billion yuan 

 

 

 

Rheumatoid arthritis is a chronic, inflammatory autoimmune diseases, can cause a series of symptoms, including pain and swelling of the joints, especially hand, foot and knee joint parts. Statistics show that China has an estimated 4 million rheumatoid arthritis patients, patients with remission rate of 8.6%, disability rates of about 50.3%. 

 

Data show that in 2015 China's urban public hospitals, public hospitals at the county level, community center of cities and towns and townships (hereinafter referred to as "China's public medical institutions") rheumatoid arthritis drug market size of more than 11.5 billion yuan. Rheumatoid arthritis drugs mainly are now a non-steroidal anti-inflammatory drugs, steroids and biology classes to relieve rheumatic drug resistance of the disease. 

 

And the main role in most other rheumatoid arthritis drugs extracellular targets, citrate for the occasional method, (citrate method for cloth) in intracellular signal transduction pathways for targets, ACTS on the core part of the cytokine network. Since folic acid for the occasional method, (citrate method for cloth) since the birth of Pfizer's own laboratory, it was the blockbuster drugs expectation. 

 

conclusion 

 

At present domestic has 28 medicine QiHuo got citrate for the occasional method, preparation (citrate method for cloth) or API approval of clinical, including rossing pharmaceutical co., the sea is, zhengda shine, qilu pharmaceutical pharmaceutical, nolato, group and other domestic well-known pharmaceutical companies, who can be listed on the first domestic product? We have to wait and see.